109 related articles for article (PubMed ID: 20088807)
1. Disaggregation of tau as a therapeutic approach to tauopathies.
Duff K; Kuret J; Congdon EE
Curr Alzheimer Res; 2010 May; 7(3):235-40. PubMed ID: 20088807
[TBL] [Abstract][Full Text] [Related]
2. Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells.
Pickhardt M; Larbig G; Khlistunova I; Coksezen A; Meyer B; Mandelkow EM; Schmidt B; Mandelkow E
Biochemistry; 2007 Sep; 46(35):10016-23. PubMed ID: 17685560
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of tau polymerization with a cyanine dye in two distinct model systems.
Congdon EE; Figueroa YH; Wang L; Toneva G; Chang E; Kuret J; Conrad C; Duff KE
J Biol Chem; 2009 Jul; 284(31):20830-9. PubMed ID: 19478088
[TBL] [Abstract][Full Text] [Related]
4. Neurofibrillary degeneration can be arrested in an in vivo cellular model of human tauopathy by application of a compound which inhibits tau filament formation in vitro.
Hall GF; Lee S; Yao J
J Mol Neurosci; 2002 Dec; 19(3):253-60. PubMed ID: 12540050
[TBL] [Abstract][Full Text] [Related]
5. Split GFP complementation assay: a novel approach to quantitatively measure aggregation of tau in situ: effects of GSK3beta activation and caspase 3 cleavage.
Chun W; Waldo GS; Johnson GV
J Neurochem; 2007 Dec; 103(6):2529-39. PubMed ID: 17908237
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationship of cyanine tau aggregation inhibitors.
Chang E; Congdon EE; Honson NS; Duff KE; Kuret J
J Med Chem; 2009 Jun; 52(11):3539-47. PubMed ID: 19432420
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau.
Li W; Sperry JB; Crowe A; Trojanowski JQ; Smith AB; Lee VM
J Neurochem; 2009 Aug; 110(4):1339-51. PubMed ID: 19549281
[TBL] [Abstract][Full Text] [Related]
8. Further understanding of tau phosphorylation: implications for therapy.
Medina M; Avila J
Expert Rev Neurother; 2015 Jan; 15(1):115-22. PubMed ID: 25555397
[TBL] [Abstract][Full Text] [Related]
9. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
10. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
Badiola N; Suárez-Calvet M; Lleó A
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
[TBL] [Abstract][Full Text] [Related]
11. Prospect of therapeutic approaches to tauopathies.
Roder HM
J Mol Neurosci; 2003 Apr; 20(2):195-202. PubMed ID: 12794313
[TBL] [Abstract][Full Text] [Related]
12. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
[TBL] [Abstract][Full Text] [Related]
13. Screening for inhibitors of tau protein aggregation into Alzheimer paired helical filaments: a ligand based approach results in successful scaffold hopping.
Larbig G; Pickhardt M; Lloyd DG; Schmidt B; Mandelkow E
Curr Alzheimer Res; 2007 Jul; 4(3):315-23. PubMed ID: 17627489
[TBL] [Abstract][Full Text] [Related]
14. Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases.
Necula M; Chirita CN; Kuret J
Biochemistry; 2005 Aug; 44(30):10227-37. PubMed ID: 16042400
[TBL] [Abstract][Full Text] [Related]
15. O-GlcNAc modification and the tauopathies: insights from chemical biology.
Yuzwa SA; Vocadlo DJ
Curr Alzheimer Res; 2009 Oct; 6(5):451-4. PubMed ID: 19874270
[TBL] [Abstract][Full Text] [Related]
16. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.
Shiryaev N; Jouroukhin Y; Giladi E; Polyzoidou E; Grigoriadis NC; Rosenmann H; Gozes I
Neurobiol Dis; 2009 May; 34(2):381-8. PubMed ID: 19264130
[TBL] [Abstract][Full Text] [Related]
17. The twenty-four KDa C-terminal tau fragment increases with aging in tauopathy mice: implications of prion-like properties.
Matsumoto SE; Motoi Y; Ishiguro K; Tabira T; Kametani F; Hasegawa M; Hattori N
Hum Mol Genet; 2015 Nov; 24(22):6403-16. PubMed ID: 26374846
[TBL] [Abstract][Full Text] [Related]
18. Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups.
Soeda Y; Yoshikawa M; Almeida OF; Sumioka A; Maeda S; Osada H; Kondoh Y; Saito A; Miyasaka T; Kimura T; Suzuki M; Koyama H; Yoshiike Y; Sugimoto H; Ihara Y; Takashima A
Nat Commun; 2015 Dec; 6():10216. PubMed ID: 26671725
[TBL] [Abstract][Full Text] [Related]
19. Hsp70 alters tau function and aggregation in an isoform specific manner.
Voss K; Combs B; Patterson KR; Binder LI; Gamblin TC
Biochemistry; 2012 Jan; 51(4):888-98. PubMed ID: 22236337
[TBL] [Abstract][Full Text] [Related]
20. Identification of key amino acids responsible for the distinct aggregation properties of microtubule-associated protein 2 and tau.
Xie C; Soeda Y; Shinzaki Y; In Y; Tomoo K; Ihara Y; Miyasaka T
J Neurochem; 2015 Oct; 135(1):19-26. PubMed ID: 26134402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
